RENALYTIX PLC LS-0025 (2O9) - Net Assets
Based on the latest financial reports, RENALYTIX PLC LS-0025 (2O9) has net assets worth €-1.20 Million EUR (≈ $-1.40 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€9.90 Million ≈ $11.57 Million USD) and total liabilities (€11.10 Million ≈ $12.98 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See RENALYTIX PLC LS-0025 balance sheet independence to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-1.20 Million |
| % of Total Assets | -12.12% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 75.97 |
RENALYTIX PLC LS-0025 - Net Assets Trend (2022–2025)
This chart illustrates how RENALYTIX PLC LS-0025's net assets have evolved over time, based on quarterly financial data. Also explore 2O9 net asset momentum to track the company's year-over-year net asset growth rate.
Annual Net Assets for RENALYTIX PLC LS-0025 (2022–2025)
The table below shows the annual net assets of RENALYTIX PLC LS-0025 from 2022 to 2025. For live market cap and overall valuation, see 2O9 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | €-7.00 Million ≈ $-8.18 Million |
+22.22% |
| 2024-06-30 | €-9.00 Million ≈ $-10.52 Million |
-229.18% |
| 2023-06-30 | €6.97 Million ≈ $8.15 Million |
-77.24% |
| 2022-06-30 | €30.61 Million ≈ $35.78 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to RENALYTIX PLC LS-0025's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3238200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €158.10 Million | % |
| Total Equity | €-7.00 Million | 100.00% |
RENALYTIX PLC LS-0025 Competitors by Market Cap
The table below lists competitors of RENALYTIX PLC LS-0025 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
MBL Infrastructure Limited
NSE:MBLINFRA
|
$39.90 Million |
|
Staatl. Mineralbrunnen AG
MU:SLB
|
$39.92 Million |
|
Touchstone Exploration Inc
TO:TXP
|
$39.93 Million |
|
Able View Global Inc. Class B Ordinary Shares
NASDAQ:ABLV
|
$39.95 Million |
|
Mangalam Organics Limited
NSE:MANORG
|
$39.89 Million |
|
Bonia Corporation Bhd
KLSE:9288
|
$39.87 Million |
|
Sangsangin Industry Co. Ltd.
KQ:101000
|
$39.84 Million |
|
PGF Polska Grupa Fotowoltaiczna SA
WAR:PGV
|
$39.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in RENALYTIX PLC LS-0025's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -9,000,000 to -7,000,000, a change of 2,000,000.
- Net loss of 20,400,000 reduced equity.
- New share issuances of 19,500,000 increased equity.
- Other factors increased equity by 2,900,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-20.40 Million | -291.43% |
| Share Issuances | €19.50 Million | +278.57% |
| Other Changes | €2.90 Million | +41.43% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares RENALYTIX PLC LS-0025's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | €0.41 | €0.06 | x |
| 2023-06-30 | €0.07 | €0.06 | x |
| 2024-06-30 | €-0.06 | €0.06 | x |
| 2025-06-30 | €-0.02 | €0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently RENALYTIX PLC LS-0025 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -680.00%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-200.64%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -147.93% | -1524.44% | 0.06x | 1.64x | €-48.34 Million |
| 2023 | -654.61% | -1340.20% | 0.11x | 4.40x | €-46.30 Million |
| 2024 | 0.00% | -1978.26% | 0.32x | 0.00x | €-44.60 Million |
| 2025 | 0.00% | -680.00% | 0.49x | 0.00x | €-19.70 Million |
Industry Comparison
This section compares RENALYTIX PLC LS-0025's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $491,008,232
- Average return on equity (ROE) among peers: -43.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| RENALYTIX PLC LS-0025 (2O9) | €-1.20 Million | -147.93% | N/A | $39.89 Million |
| YIDU TECH INC. DL -00002 (0EL) | $4.16 Billion | -15.11% | 0.18x | $414.88 Million |
| CERTIVE SOLUTIONS INC. (5CE) | $-9.11 Million | 0.00% | 0.00x | $253.72K |
| UPHEALTH INC (5XV) | $106.14 Million | -210.11% | 2.20x | $5.44 Million |
| IQ-AI LTD. LS -01 (5Y1) | $407.62K | -98.36% | 1.49x | $123.35K |
| Victory Square Technologies Inc (6F6) | $38.70 Million | 51.45% | 0.10x | $36.29 Million |
| NIGHTINGALE HEALTH EO 1 (7XE) | $82.88 Million | -21.07% | 0.10x | $46.72 Million |
| TRELLUS HEALTH LS -0006 (85Q) | $19.50 Million | -32.51% | 0.04x | $215.06K |
| SPOTLITE360 IOT SOLUTIONS (87A0) | $5.83 Million | -68.78% | 0.33x | $916.43K |
| DocCheck AG (AJ91) | $18.57 Million | 3.29% | 0.16x | $56.32 Million |
About RENALYTIX PLC LS-0025
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for clinical management of kidney diseases in Europe and the United States. It offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from … Read more